Vemircopan
- Generic Name
- Vemircopan
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28BrN7O3
- CAS Number
- 2086178-00-7
- Unique Ingredient Identifier
- HN6I4K50QB
Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06071442
- Locations
- πΊπΈ
Research Site, Brooklyn, Maryland, United States
Study of ALXN2050 in Participants With Hepatic Impairment
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05259085
- Locations
- πΊπΈ
Research Site, Orlando, Florida, United States
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
Phase 2
Terminated
- Conditions
- Generalized Myasthenia GravisMyasthenia Gravis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05218096
- Locations
- π¨π³
Research Site, Taoyuan City, Taiwan
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT05202145
- Locations
- πΊπΈ
Clinical Study Site, Tempe, Arizona, United States
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Phase 2
Terminated
- Conditions
- Lupus NephritisIgANLNImmunoglobulin A Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05097989
- Locations
- π¬π§
Research Site, Newcastle upon Tyne, United Kingdom
A Study of Multiple Doses of ALXN2050 in Healthy Adults
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05047484
- Locations
- π³πΏ
Clinical Trial Site, Auckland, New Zealand
A Study of Single-dose ALXN2050 in Healthy Adults
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05047458
- Locations
- π³πΏ
Clinical Trial Site, Auckland, New Zealand
Study of ALXN2050 in Healthy Adult Participants of Japanese Descent
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04952545
- Locations
- πΊπΈ
Clinical Trial Site, Tempe, Arizona, United States
Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2022-12-08
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04933682
- Locations
- πΊπΈ
Clinical Trial Site, Tempe, Arizona, United States
A Drug Interaction Study of ACH-0145228
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT04709081
- Locations
- πΊπΈ
Clinical Study Site, Tempe, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath